AZD1080, a novel GSK-3β inhibitor, has been reported to play a pivotal role in attenuating the downstream detrimental effects of signaling pathways activated by multiple stimuli relevant to Alzheimer's disease [34]. This evidence concerns the gene GSK3B and early-onset autosomal dominant Alzheimer disease.